3-[6-(Cyclopropylmethoxy)pyridin-3-yl]oxypyrrolidin-2-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-[6-(Cyclopropylmethoxy)pyridin-3-yl]oxypyrrolidin-2-one
• 英文别名: 3-[6-(cyclopropylmethoxy)pyridin-3-yl]oxypyrrolidin-2-one
• 化学式: C₁₃H₁₆N₂O₃
• 分子量: 248.28
• InChiKey: MFMVRPHQRMNKFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
  申请人：SANOFI

  公开号：US20180237419A1

  公开（公告）日：2018-08-23

  The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本公开涉及氮杂环丙烷化合物。这些氮杂环丙烷化合物是GPR119调节剂，对于预防和/或治疗糖尿病、肥胖、血脂异常及相关疾病具有用处。此外，本公开还涉及将氮杂环丙烷化合物用作药物中的活性成分，以及包含它们的药物组合物。
• [EN] ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS<br/>[FR] COMPOSÉS D'ISOINDOLINONE UTILISÉS COMME MODULATEURS DE GPR119 POUR LE TRAITEMENT DU DIABÈTE, DE L'OBÉSITÉ ET DE TROUBLES ASSOCIÉS
  申请人：SANOFI SA

  公开号：WO2015150565A1

  公开（公告）日：2015-10-08

  The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及异吲哚啉酮化合物。这些异吲哚啉酮化合物是GPR119调节剂，可用于预防和/或治疗糖尿病、肥胖、血脂异常和相关疾病。此外，本发明还涉及将异吲哚啉酮化合物用作药物的活性成分，以及包含它们的药物组合物。
• PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
  申请人：SCHWINK Lothar

  公开号：US20140099333A1

  公开（公告）日：2014-04-10

  The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及吡咯烷酮衍生物。这些吡咯烷酮衍生物是GPR119调节剂，适用于预防和/或治疗糖尿病、肥胖、血脂异常及相关疾病。此外，本发明还涉及将吡咯烷酮衍生物用作药物中的活性成分，以及包含它们的药物组合物。
• [EN] PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS<br/>[FR] DÉRIVÉS DE PYRROLIDINONE À TITRE DE MODULATEURS DE GPR119 POUR LE TRAITEMENT DU DIABÈTE, DE L'OBÉSITÉ, DE LA DYSLIPIDÉMIE ET AUTRES AFFECTIONS APPARENTÉES
  申请人：SANOFI SA

  公开号：WO2014056938A1

  公开（公告）日：2014-04-17

  The present invention relates to pyrrolidinone derivatives of formula (I). The pyrrolidinone derivatives of formula (I) are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式（I）的吡咯烷酮衍生物。式（I）的吡咯烷酮衍生物是GPR119调节剂，用于预防和/或治疗糖尿病、肥胖、血脂异常及相关疾病。此外，本发明还涉及将吡咯烷酮衍生物用作药物中的活性成分，以及包含它们的药物组合物。
• [EN] SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS<br/>[FR] HÉTÉROCYCLES SUBSTITUÉS LIÉS PAR FUSION EN TANT QUE MODULATEURS GPR119 POUR LE TRAITEMENT DU DIABÈTE, DE L'OBÉSITÉ, DE LA DYSLIPIDÉMIE ET DE TROUBLES ASSOCIÉS
  申请人：SANOFI SA

  公开号：WO2015150564A1

  公开（公告）日：2015-10-08

  The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR1 19 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及替代的融合杂环化合物。这些替代的融合杂环化合物是GPR1 19调节剂，对于预防和/或治疗糖尿病、肥胖、血脂异常及相关疾病非常有用。此外，本发明还涉及将替代的融合杂环化合物作为药物中的活性成分使用，以及包含它们的药物组合物。